Table 4.
Source of Tregs at specified post-transplantation time points.
| Patient ID | E/R | HDMC/LDMC | Distinguishable HLA | PT time point | TregsRecipient (%) | TregsDonor(%) | Mixed Chimerism present |
|---|---|---|---|---|---|---|---|
| 225-19 | E | HDMC | Recipient is A3+ | PT-Day30 | 100 | 0 | No |
| HDMC | PT-Day60 | 100 | 0 | No | |||
| HDMC | PT-Day180 | 100 | 0 | No | |||
| 225-43 | E | HDMC | Donor is A2+ | PT-Day30 | 99 | 1 | Yes |
| HDMC | PT-Day60 | 99 | 1 | Yes | |||
| HDMC | PT-Day180 | 98 | 2 | Yes | |||
| 225-51 | E | HDMC | Donor is A2+ | PT-Day60 | 100 | 0 | No |
| HDMC | PT-Day100 | 100 | 0 | No | |||
| HDMC | PT-Day180 | 100 | 0 | No | |||
| 225-44 | E | HDMC | Donor is A2+ | PT-Day30 | 93 | 7 | Yes |
| HDMC | PT-Day60 | 99 | 1 | Yes | |||
| HDMC | PT-Day100 | 100 | 0 | No | |||
| HDMC | PT-Day180 | 96 | 4 | Yes | |||
| 225-10 | R | LDMC | Donor is A3+ | PT-Day30 | 100 | 0 | No |
| LDMC | PT-Day60 | 100 | 0 | No | |||
| LDMC | PT-Day100 | 100 | 0 | No | |||
| 225-52 | R | LDMC | Donor is A3+ | PT-Day30 | 100 | 0 | No |
| LDMC | PT-Day60 | 100 | 0 | No | |||
| LDMC | PT-Day100 | 100 | 0 | No | |||
| LDMC | PT-Day180 | 100 | 0 | No | |||
| 225-55 | R | LDMC | Donor is A2+ | PT-Day60 | 100 | 0 | No |
| LDMC | PT-Day100 | 100 | 0 | No | |||
| LDMC | PT-Day180 | 100 | 0 | No | |||
| 225-36 | R | HDMC | Donor is A2+ | PT-Day30 | 100 | 0 | No |
| HDMC | PT-Day60 | 100 | 0 | No | |||
| LDMC | PT-Day100 | 100 | 0 | No | |||
| LDMC | PT-Day180 | 100 | 0 | No | |||
| 225-40 | R | HDMC | Donor is A2+ | PT-Day30 | 100 | 0 | No |
| LDMC | PT-Day60 | 100 | 0 | No | |||
| LDMC | PT-Day100 | 100 | 0 | No | |||
| LDMC | PT-Day100 | 95 | 5 | Yes |
Table showing the presence or absence of mixed chimerism in Tregs at HDMC and LDMC time points (chi-square =2.63; P< 0.10, Yates correction applied). No differences were observed between the two groups.
E, engrafted; R, Rejected; HDMC, high donor myeloid chimerism; LDMC, low donor myeloid chimerism; PT, post-transplant.